Opinion|Videos|March 6, 2025
Tailoring Chemoradiotherapy Approaches in Unresectable Stage III NSCLC
This segment transitions to discussing the management of unresectable non–small cell lung cancer (NSCLC), focusing on the distinctions between concurrent and sequential chemoradiation. It highlights patient selection, treatment tolerability, the role of advanced radiation technologies, and considerations for minimizing adverse effects while ensuring optimal outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you select patients with unresectable stage 3 NSCLC for sequential vs concurrent chemoradiotherapy (cCRT)? How do available data help inform your treatment decision?
- PACIFIC: 5-year follow-up data
- PACIFIC-R
- PACIFIC-6
- How do you manage patients not suitable for cCRT?
Advertisement
Related to this article
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5